Literature DB >> 26428517

Dissolution Similarity Requirements: How Similar or Dissimilar Are the Global Regulatory Expectations?

Dorys Argelia Diaz1, Stephen T Colgan2, Connie S Langer2, Nagesh T Bandi3, Michael D Likar4, Leslie Van Alstine4.   

Abstract

The objective of this article is to compare and contrast the international expectations associated with the model-independent similarity factor approach to comparing dissolution profiles. This comparison highlights globally divergent regulatory requirements to meet local dissolution similarity requirements. In effect, experiments customized to meet the current international regulatory expectations for dissolution and drug release unnecessarily increase manufacturing costs, hinder science and risk-based approaches, increase collective regulatory burden, reduce continuous improvement and innovation, and potentially delay patient access to urgently needed medication. Comparative assessment of regulatory differences in applying dissolution to demonstrate product similarity is crucial to reduce non-scientifically justified experiments and foster collaborative harmonization among global regulatory health authorities and the pharmaceutical industry.

Entities:  

Keywords:  chemistry manufacturing and controls (CMC); comparative dissolution; f 2; global; regulatory; similarity factor

Mesh:

Year:  2015        PMID: 26428517      PMCID: PMC4706290          DOI: 10.1208/s12248-015-9830-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  6 in total

1.  Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.

Authors:  Qing Liu; Barbara M Davit; Svetlana A Cherstniakova; Suman Dandamudi; Johnetta F Walters; Christina H Lee; Kimberly W Raines; Ke Ren; Leeh N Williamson; Dale P Conner
Journal:  AAPS J       Date:  2011-12-01       Impact factor: 4.009

Review 2.  Review of global regulations concerning biowaivers for immediate release solid oral dosage forms.

Authors:  E Gupta; D M Barends; E Yamashita; K A Lentz; A M Harmsze; V P Shah; J B Dressman; R A Lipper
Journal:  Eur J Pharm Sci       Date:  2006-05-10       Impact factor: 4.384

3.  In vitro dissolution profile comparison--statistics and analysis of the similarity factor, f2.

Authors:  V P Shah; Y Tsong; P Sathe; J P Liu
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

4.  In-vitro dissolution profile comparison: statistics and analysis, model dependent approach.

Authors:  P M Sathe; Y Tsong; V P Shah
Journal:  Pharm Res       Date:  1996-12       Impact factor: 4.200

5.  In vitro dissolution similarity factor (f2) and in vivo bioequivalence criteria, how and when do they match? Using a BCS class II drug as a simulation example.

Authors:  Feifan Xie; Shan Ji; Zeneng Cheng
Journal:  Eur J Pharm Sci       Date:  2014-10-12       Impact factor: 4.384

6.  Progressively reducing regulatory burden.

Authors:  Vinod P Shah; Todd L Cecil; Srini V Srinivasan; Roger L Williams
Journal:  AAPS J       Date:  2014-04-17       Impact factor: 4.009

  6 in total
  18 in total

1.  A Simple Approach for Comparing the In Vitro Dissolution Profiles of Highly Variable Drug Products: a Proposal.

Authors:  Marilyn N Martinez; Xiongce Zhao
Journal:  AAPS J       Date:  2018-06-25       Impact factor: 4.009

2.  Analysis of the Regulatory Divergence of Comparative Dissolution Requirements for Post-Approval Manufacturing Changes of Modified Release Solid Oral Dosage Forms.

Authors:  Connie Langer; Dorys Argelia Diaz; Leslie Van Alstine; Nagesh Bandi; Sarah Fitzgerald; Stephen Colgan
Journal:  AAPS J       Date:  2019-11-04       Impact factor: 4.009

3.  Biowaiver Applications in Support of a Polymorph During Late-Stage Clinical Development of Verubecestat-Current Challenges and Future Opportunities for Global Regulatory Alignment.

Authors:  Andreas Abend; Leah Xiong; Xiaohua Zhang; Celeste Frankenfeld; Filippos Kesisoglou; Kevin Reuter; Pramod Kotwal
Journal:  AAPS J       Date:  2019-12-20       Impact factor: 4.009

4.  Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.

Authors:  Mai Khanfar; Mayyas Al-Remawi; Faisal Al-Akayleh; Suha Hmouze
Journal:  AAPS PharmSciTech       Date:  2021-03-21       Impact factor: 3.246

5.  Did Generic Clopidogrel Commercialization Affect Trends of ER Consultations and Hospitalizations in the Population Treated with Clopidogrel?

Authors:  Jacinthe Leclerc; Claudia Blais; Louis Rochette; Denis Hamel; Line Guénette; Paul Poirier
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

6.  Three-dimensional porous calcium alginate fluorescence bead-based immunoassay for highly sensitive early diagnosis of breast cancer.

Authors:  Ying Yao Chia; T Malathi Theverajah; Yatimah Alias; Sook Mei Khor
Journal:  Anal Bioanal Chem       Date:  2021-11-27       Impact factor: 4.142

7.  Development of Apremilast Nanoemulsion-Loaded Chitosan Gels: In Vitro Evaluations and Anti-Inflammatory and Wound Healing Studies on a Rat Model.

Authors:  Mohammed Muqtader Ahmed; Md Khalid Anwer; Farhat Fatima; Amer S Alali; Mohd Abul Kalam; Ameeduzzafar Zafar; Sultan Alshehri; Mohammed M Ghoneim
Journal:  Gels       Date:  2022-04-20

8.  Levodopa-carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation.

Authors:  Matthew Rosebraugh; Hari V Kalluri; Wei Liu; Charles Locke; Dilraj Sidhu; Jian-Hwa Han; Janet Benesh
Journal:  Pharmacol Res Perspect       Date:  2019-04

9.  Stoichiometrically Governed Curcumin Solid Dispersion and Its Cytotoxic Evaluation on Colorectal Adenocarcinoma Cells.

Authors:  Jamal Moideen Muthu Mohamed; Ali Alqahtani; Fazil Ahmad; V Krishnaraju; K Kalpana
Journal:  Drug Des Devel Ther       Date:  2020-11-02       Impact factor: 4.162

10.  Calcium Chloride Modified Alginate Microparticles Formulated by the Spray Drying Process: A Strategy to Prolong the Release of Freely Soluble Drugs.

Authors:  Marta Szekalska; Katarzyna Sosnowska; Anna Czajkowska-Kośnik; Katarzyna Winnicka
Journal:  Materials (Basel)       Date:  2018-08-24       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.